Whats New With HER2 Charting New Paths in NSCLC Care - Module 1
Tracking # 20-1288680
Course overview
Stay ahead in NSCLC management with this microlearning series! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions. Module 1, provides essential insights and testing recommendations to optimize patient care. STATEMENT OF NEED With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and their differing implications for targeted therapy can pose challenges (Uy et al, 2022). Therefore, it is crucial for clinicians to remain up to date on emerging biomarker testing guidelines and methodologies in order to plan optimal treatment strategies for their patients. In Module 1 of this activity, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, will explore actionable insights and testing recommendations for HER2 alterations in NSCLC. TARGET AUDIENCE Oncologists, pulmonologists, oncology nurses, advanced practice providers, and other health care professionals involved in the treatment of patients with non small cell lung cancer (NSCLC). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to Discuss the significance of HER2 mutations in NSCLC and their implications for treatment planning Identify methods for detecting HER2 mutations in NSCLC and adherence to biomarker testing guidelines
Subject areas
This course counts toward the state boards and subject areas below.
Arkansas State Board of Nursing
Certified Nurse Practitioner
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
Registered Nurse Practitioner
New Hampshire Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
New Mexico Board of Nursing
Certified Nurse Practitioner
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
North Dakota Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
South Carolina Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Disclosure statements
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Julia Kathleen Rotow, MD, discloses that she has served as a consultant or on an advisory board or panel for Amgen, AstraZeneca, BioAtla, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Genentech, Jazz, Johnson & Johnson, Merus, Pfizer, Summit, and Takeda; that she has received grants/research support from AbbVie, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond, Blueprint, Daiichi Sankyo, Empim Ab, Enliven, Loxo Oncology, ORIC, RedCloud, Summit, and Synthekine; and that she has received other financial or material support (royalties, patents, etc.) from AstraZeneca and Pfizer.
i3 Health has mitigated all relevant financial relationships.